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Introduction: Single-nucleotide polymorphisms (SNPs) associated with hepatitis C virus
(HCV) clearancewere identiﬁed near the IL28B gene. Coinfection by the human immunode-
ﬁciency virus (HIV) inﬂuences the course ofHCV contributing to liver damage. Nevertheless,
little is known about the relationship between these SNPs and HCV/HIV coinfection. Our
aim was to estimate the frequencies of the allelic and genotypic variants of the IL28B
polymorphisms rs12979860 (C /T ) and rs8099917 (T /G) and their possible association with
the establishment of HCV infection.
Methodology: A total of 199 non-infected controls and 230 patients with chronic hepatitis
C, including 53 coinfected with HIV, participated in the study. Genotyping consisted of
polymerase chain reaction and subsequent analysis of the restriction patterns resulting
from exposure to endonucleases.
Results: Among the controls with established results, 47.4% (90/190) exhibited the
rs12979860 CC genotype, 43.7 CT, and 8.9% TT, whereas 29.1% (66/227), 51.5%, and
19.4% of the patients exhibited the CC, CT, andTT genotypes, respectively.With respect
to rs8099917, 66.8% (133/199) of the controls exhibited the TT genotype, 31.2% TG, and
2.0% GG, whereas 56.1% (129/230), 40.9%, and 3.0% of the patients exhibited the TT,
TG, and GG genotypes, respectively.
Conclusion: The frequencies of the rs12979860 C allele and CC genotype and of the
rs8099917 T allele and TT genotype were signiﬁcantly higher among controls compared
with patients, thus conﬁrming the suggested protective effect against HCV infection. No
signiﬁcant difference was observed in the genotype and allelic distributions between the
mono- and coinfected patients.
Keywords: hepatitis C, HIV, HCV–HIV coinfection, IL28B gene, single nucleotide polymorphisms (SNPs)
INTRODUCTION
Hepatitis C is caused by the hepatitis C virus (HCV), an enveloped,
single-stranded RNA virus that belongs to the family Flaviviri-
dae (World Health Organization [WHO], 2014). Approximately
70–80% of HCV infections become chronic; only a small frac-
tion of infected individuals exhibit spontaneous viral clearance.
The patients with active persistent infection are at high risk of
developing cirrhosis and hepatocellular carcinoma (Seeff, 2002).
The most cost effective means of controlling infectious disease
is through vaccination, however, a prophylactic or therapeutic
vaccine for HCV is not available yet (Drummer, 2014). Until
2011, the standard treatment of chronic hepatitis C consists of
a combination of pegylated interferon-α (PegIFN-α-2a/2b) and
ribavirin (RBV). However, the efﬁcacy of the standard treatment
was limited, as only 45–55%of the patients infected byHCV geno-
type 1 achieved the sustained virological response (SVR)(García
et al., 2001). After 2011, direct antiviral agents (DAAs) for the
treatment of patients with HCV genotype 1 became available in
many countries, namely boceprevir (BOC) and telaprevir (TVR),
used in combination with PegIFN and RBV, called triple-therapy,
to improve cure rates (Bacon et al., 2011; Jacobson et al., 2011;
Poordad et al., 2011).
Every year, 3–4 millions of people worldwide are infected by
the HCV, and the number of individuals with chronic infection
is estimated to be approximately 130–150 million (World Health
Organization [WHO], 2014). In Brazil, the estimated number of
individuals with hepatitis C is two million (Ciorlia and Zanetta,
2007). The prevalence of the human immunodeﬁciency virus
(HIV) infection among HCV-infected individuals is high, largely
because the major viral transmission pathways are the same for
these infections. For instance, in US and Western Europe, the
prevalence of the coinfection is as elevated as 72% to 95% among
injection drug users (Operskalski and Kovacs, 2011). Coinfection
is characterized by the impact of HIV on the natural course of
HCV infection and vice-versa. HIV accelerates the progression of
liver disease in HCV-infected individuals, thus increasing the risk
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of cirrhosis and viremia rates while reducing the odds of attaining
an SVR to interferon-based treatment (Martino et al., 2001; Silva
and Barone, 2006).
Ge et al. (2009), Tanaka et al. (2009), and Thomas et al. (2009)
were the ﬁrst to identify Single Nucleotide Polymorphisms (SNPs)
near the IL28B gene on chromosome 19 that exhibit strong
associations with HCV clearance. The CC rs12979860 and TT
rs8099917 genotypes are associated with a signiﬁcant increase in
the rate of spontaneous resolution of HCV infection as well as
increased odds of attaining SVR in mono- and coinfected patients
(Aparicio et al., 2010; Rállon et al., 2010; Lunge et al., 2012). In
addition, Ge et al. (2009) determined that the C allele frequency
of the rs12979860 was signiﬁcantly reduced in a group of patients
with chronic hepatitis C compared to a matched control group
(p < 2.5 × 10−6).
Despite the evidence of the relevance of polymorphisms
rs12979860 and rs8099917 in hepatitis C, there have been few
studies on their prevalence in different groups of individu-
als. Additionally, few studies have investigated the inﬂuence
of SNPs on the establishment of HCV infection in individu-
als also infected with HIV. Thus, the aim of the study was to
estimate the frequencies of the allelic and genotypic variants
of the IL28B polymorphisms rs12979860 (C/T) and rs8099917
(T/G) and their possible association with the establishment of
HCV infection in HCV mono-infected and HCV/HIV coinfected
patients.
MATERIALS AND METHODS
STUDY POPULATION AND DNA EXTRACTION
Individuals with serological evidence of non-exposure to HCV
and HIV were recruited among blood donors and composed the
control group. The HCV mono-infected and the HCV/HIV-1
coinfected patients were consecutively recruited at Hospital Uni-
versitário Gaffrée & Guinle (Rio de Janeiro, RJ, Brazil), reﬂecting
the local casuistic.
The peripheral blood collected by ﬁnger puncture from mono-
and coinfected patients was collected using ﬁlter paper (FTA Elute
Micro Card®,Whatman, Kent, UK). To extract the genomic DNA,
3-mm diameter disks were removed from the cards and pro-
cessed according to the manufacturer’s instructions. SNP-based
genotyping for rs12979860 was performed in 190 non-infected
individuals and 227 patients, 52 of whom were coinfected. In
addition, SNP-based genotyping for rs8099917 was performed
in 199 non-infected individuals and 230 patients, 53 of whom
were coinfected. The study was approved by the Research Ethics
Committee of Universidade da Região de Joinville (UNIVILLE;
protocol 136/10). Informed consent was obtained from each
participant before blood sampling.
GENETIC ANALYSIS
The rs12979860 and rs8099917 SNP variants were identiﬁed as
developed by Moreira et al. (2012). First, polymerase chain reac-
tion (PCR) was performed in the LGC XP thermocycler (BIOER
Technology Co., Tokio, Japan) using speciﬁc oligonucleotides
to obtain the genetic segments containing the SNPs rs12979860
and rs8099917. The amplicons containing SNPs rs12979860
and rs8099917 were 694 and 496 base pairs (bp), respectively.
The amplicons were subjected to Restriction Fragment Length
Polymorphism (RFLP) analysis using the BsrDI and Hpy166II
endonucleases (New England Biolabs, Beverly, MA, USA) for
rs12979860 and rs8099917, respectively. Finally, the products of
enzymatic digestion were subjected to agarose gel electrophore-
sis. The results were visualized using MiniBis-Pro documenta-
tion system (DNR Bio-Imaging Systems Ltd., Jerusalem, Israel).
Thus, the genotype of each investigated individual was estab-
lished based on the analysis of the electrophoretic proﬁle: CC
homozygous (two fragments of 509 and 185 bp), TT homozy-
gous (509, 155, and 30 bp), or CT heterozygous (509, 185,
155, and 30 bp) for rs12979860 and TT homozygous (496 bp),
GG homozygous (272 and 224 bp), or GT heterozygous (496,
272, and 224 bp) for rs8099917. PCR and RFLP analyses were
performed independently for each investigated polymorphism,
thus representing two separate procedures. All of the analy-
ses were performed at the Laboratory of Molecular Biology of
UNIVILLE.
TREATMENT OF DATA AND STATISTICAL ANALYSIS
The adherence of the identiﬁed genotype frequencies to the
Hardy–Weinberg theoretical proportions, the SNP linkage dis-
equilibrium analysis, and the allelic and genotype frequen-
cies of each polymorphism in cases and controls were esti-
mated using the software GENEPOP version 3.4 (available
at www.biomed.curtin.edu.au/genepop)(Raymond and Rousset,
1995). Linkage disequilibrium and Hardy–Weinberg equilibrium
were deﬁned by p-values lower and higher than 0.05, respectively.
The association of the genotypes with the susceptibility to HCV
infection was established based on 2 × 2 contingency tables by
means of the Odds Ratio (OR) with 95% Conﬁdence Intervals
(95% CI), considering p-values lower than 0.05 to be signiﬁcant
(Woolf, 1955). This test was performed using the Epimax Table
Calculator software (Health Decision Strategies [HDS], 2013).
The HCV mono- and coinfected patients were subjected to both
joint and separate analyses to assess the inﬂuence of HIV on the
results.
RESULTS
CHARACTERISTICS OF THE STUDY POPULATION
HIV-infected patients were receiving successful antiretroviral ther-
apy and had an undetectable viral load at the time of blood
sampling. The demographic and virological characteristics of the
patients chronically mono-infected with HCV, those coinfected
with HIV-1, and the non-infected individuals are described in
Table 1.
POLYMORPHISMS rs12979860 AND rs8099917 AND LINKAGE
DISEQUILIBRIUM
The analysis of the probability of segregation between polymor-
phic sites was performed by means of the linkage disequilibrium
test. The investigated SNPs (rs12979860 and rs8099917) proved
to be ligated in all of the populations compared in the present
study: non-infected individuals vs. coinfected patients; non-
infected individuals vs. mono-infected patients; and coinfected
vs. mono-infected patients. All of these comparisons exhibited
p-values lower than 0.05.
Frontiers in Microbiology | Infectious Diseases March 2015 | Volume 6 | Article 153 | 2
Bertol et al. IL28B polymorphisms in hepatitis C
Table 1 | Demographic and virological characteristics of study population.
Controls Patients (total) HCV patients HCV/HIV-1 patients
Mean age (years ± SD) 34.3 ± 10.61 55.2 ± 9.88 56.8 ± 9.60 50 ± 9.13
Gender
Female
Male
68/199 (34.2%)
131/199 (65.8%)
91/226 (40.3%)
135/226 (59.7%)
81/173 (46.8%)
92/173 (53.2%)
10/53 (18.9%)
43/53 (81.1%)
HCV genotype
1
Others
–
–
210/218 (96.3%)
8/218 (3.7%)
157/165 (95.1%)
8/165 (4.9%)
53/53 (100%)
–
SD, standard deviation.
POLYMORPHISM rs12979860 IN NON-INFECTED INDIVIDUALS AND
PATIENTS
Thedistribution frequencyof the SNP rs12979860 among thenon-
infected individuals and patients complied with Hardy–Weinberg
equilibrium. Table 2 describes the genotypic and allelic frequen-
cies exhibited by the non-infected individuals and by the mono-
and coinfected patients with chronic hepatitis C.
Signiﬁcant differences were observed in the genotype fre-
quencies; the CC genotype was more prevalent in non-infected
individuals (47.4%, p < 0.001) compared to the whole group
(mono- and coinfected) of patients (29.1%). In addition, the C
allele was observed more frequently in non-infected individuals
(69.2%, p < 0.001) than in the patients group (54.9%). An anal-
ysis of the relative risk of this SNP relative to the susceptibility
to viral infection revealed an OR of 2.447 (p = 0.005) for the TT
genotype alone and an OR of 2.195 (p < 0.001) for the genotypes
containing at least one T allele (TT and CT) in the chronic hepati-
tis C population (mono- and coinfected patients taken together).
Similar result was obtained in the analysis of the relative risk of T
allele (OR = 1.851, p < 0.001).
Signiﬁcant differences were also observed in the distribution of
alleles and genotypes in non-infected individuals compared to the
mono- and coinfected patientswhen analyzed separately (Table 2).
The CC genotype was more frequent in non-infected individu-
als (47.4%) compared to mono-infected (30.9%, p < 0.001) and
coinfected (23.5%, p = 0.007) patients. Additionally, the C allele
was more frequently observed in non-infected patients (69.2%)
compared with both groups of patients (mono-infected – 54.9%,
p < 0.001; coinfected – 54.8%, p = 0.009). An analysis of the
relative risk of this SNP in the group of mono-infected patients
indicated an OR of 2.728 (p = 0.002) for the TT genotype, an OR
of 2.017 (p = 0.002) for genotypes containing at least one allele
T (TT and CT), and an OR of 1.852 (p < 0.001) for the T allele.
In the group of coinfected patients, the TT genotype, TT+CT
genotypes, and T allele exhibited ORs of 1.583 (p = 0.482), 3.000
(p = 0.003), and 1.846 (p = 0.009), respectively.
No signiﬁcant difference was observed in the distributions of
the CC genotype (30.9% vs. 23.5%, p = 1.000) and the C allele
(54.9% vs. 54.8%, p = 1.000) between the groups of mono- and
coinfected patients, respectively. Neither risk factor analysis indi-
cated any relevant risk for either genotypes (TT vs. CT+CC,
OR = 0.58, p = 0.303; TT+CT vs. CC, OR = 1.488, p = 0.363) or
alleles (OR = 1.002, p = 1.000).
POLYMORPHISM rs8099917 IN NON-INFECTED INDIVIDUALS AND
PATIENTS
The distribution frequency of the SNP rs8099917 among the non-
infected individuals and patients complied with Hardy–Weinberg
equilibrium. Table 3 describes the genotypic and allelic frequen-
cies of non-infected individuals and mono- or coinfected patients
with chronic hepatitis C.
Similar to rs12979860, signiﬁcant differences were found in the
distribution of frequencies of rs8099917 variants; theTT genotype
was more frequently observed in non-infected individuals (66.8%,
p = 0.033) compared with the whole group of patients (56.1%).
In addition, the T allele was observed more frequently in non-
infected individuals (82.4%, p = 0.048) compared with the group
of mono- and coinfected patients (76.5%). An analysis of the rel-
ative risk of this SNP relative to the susceptibility to viral infection
identiﬁed an OR of 1.530 (p = 0.712) for the GG genotype alone
and an OR of 1.578 (p = 0.029) for the genotypes containing at
least one allele G (GG and TG) in the patients with chronic hep-
atitis C (mono- and coinfected patients together). Similar result
was obtained in the analysis of the relative risk of the G allele
(OR = 1.438, p = 0.041).
Signiﬁcant differences were also observed in the distribution
of genotypes and alleles in non-infected individuals compared
with the group of mono-infected patients (Table 3). As before,
the TT genotype was observed signiﬁcantly more often in non-
infected individuals (66.8%, p = 0.012), as well as T allele (82.4%,
p < 0.001), compared with the group of mono-infected patients
(54.2 and 75.4%, respectively). However, these differences were
not observed when the non-infected individuals were compared
with the coinfected patients. An analysis of the relative risk of this
SNP relative to the susceptibility to viral infection in the mono-
infected patients indicated an OR of 1.711 (p = 0.610) for the GG
genotype alone, an OR of 1.700 (p = 0.017) for the genotypes
containing at least one allele G (GG and TG), and an OR of 1.527
(p = 0.024) for the G allele. In the coinfected patients, the ORs of
the GG genotype, the GG+TG genotypes, and the G allele were
0.938 (p = 1.000), 1.221 (p = 0.645), and 1.158 (p = 0.699),
respectively, without statistical signiﬁcance.
As with rs12979860, we observed no signiﬁcant differences in
the distribution of the TT genotype (54.2% vs. 62.3%, p = 0.327)
or the T allele (75.4% vs. 80.2%, p = 0.357) between the mono-
infected and coinfected patients, respectively. Neither risk factor
analysis revealed signiﬁcant differences with respect to either the
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Table 2 | Allelic and genotypic frequencies and association analysis – rs12979860.
Controls (n = 190) Patients (total) (n = 227) Comparison OR (CI 95%) p
Genotype
CC 90 (47.4%) 66 (29.1%) – – –
CT 83 (43.7%) 117 (51.5%) TT+CT vs. CC 2.195 (1.437–3.357) <0.001*
TT 17 (8.9%) 44 (19.4%) TT vs. CT+CC 2.447 (1.300–4.648) 0.005*
p – <0.001A* – – –
Allele
C 263 (69.2%) 249 (54.9%) – – –
T 117 (30.8%) 205 (45.1%) T vs. C 1.851 (1.377–2.488) <0.001*
p – <0.001B* – – –
Controls (n = 190) HCV patients (n = 175) Comparison OR (CI 95%) p
Genotype
CC 90 (47.4%) 54 (30.9%) – – –
CT 83 (43.7%) 84 (48.0%) TT+CT vs. CC 2.017 (1.284–3.170) 0.002*
TT 17 (8.9%) 37 (21.1%) TT vs. CT+CC 2.728 (1.417–5.296) 0.002*
p – <0.001C* – – –
Allele
C 263 (69.2%) 192 (54.9%) – – –
T 117 (30.8%) 158 (45.1%) T vs. C 1.850 (1.351–2.534) <0.001*
p – <0.001D* – – –
Controls (n = 190) HCV/HIV-1 patients (n = 52) Comparison OR (CI 95%) p
Genotype
CC 90 (47.4%) 12 (23.5%) – – –
CT 83 (43.7%) 33 (62.8%) TT+CT vs. CC 3.000 (1.413–6.469) 0.003*
TT 17 (8.9%) 7 (13.7%) TT vs. CT+CC 1.583 (0.556–4.374) 0.482
p – 0.007E* – – –
Allele
C 263 (69.2%) 57 (54.8%) – – -
T 117 (30.8%) 47 (45.2%) T vs. C 1.854 (1.162–2.957) 0.009*
p – 0.009F* – – –
HCV patients (n = 175) HCV/HIV-1 patients (n = 52) Comparison OR (CI 95%) p
Genotype
CC 54 (30.9%) 12 (23.5%) – – –
CT 84 (48.0%) 33 (62.8%) TT+CT vs. CC 1.488 (0.688–3.263) 0.363
TT 37 (21.1%) 7 (13.7%) TT vs. CT+CC 0.580 (0.219–1.479) 0.303
p – 1.000G – – –
Allele
C 192 (54.9%) 57 (54.8%) – – –
T 158 (45.1%) 47 (45.2%) T vs. C 1.002 (0.630–1.592) 1.000
p – 1.000H – – –
A,BControls vs. Patients (total); C,DControls vs. HCV Patients; E,FControls vs. HCV/HIV-1 Patients; G,HHCV Patients vs; HCV/HIV-1 Patients; OR, Odds ratio; CI,
Conﬁdence intervals. *Statistical signiﬁcance.
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Table 3 | Allelic and genotypic frequencies and association analysis – rs8099917.
Controls (n = 199) Patients (total) (n = 230) Comparison OR (CI 95%) p
Genotype
TT 133 (66.8%) 129 (56.1%) – – –
TG 62 (31.2%) 94 (40.9%) GG+TG vs. TT 1.578 (1.044–2.385) 0.029*
GG 4 (2.0%) 7 (3.0%) GG vs. TG+TT 1.530 (0.396–6.314) 0.712
p – 0.033A* – – –
Allele
T 328 (82.4%) 352 (76.5%) – – –
G 70 (17.6%) 108 (23.5%) G vs. T 1.438 (1.013–2.041) 0.041*
p – 0.048B* – – –
Controls (n = 199) HCV patients (n = 277) Comparison OR (CI 95%) p
Genotype
TT 133 (66.8%) 96 (54.2%) – – –
TG 62 (31.2%) 75 (42.4%) GG+TG vs. TT 1.700 (1.096–2.640) 0.017*
GG 4 (2.0%) 6 (3.4%) GG vs. TG+TT 1.711 (0.420–7.344) 0.610
p – 0.012C* – – –
Allele
T 328 (82.4%) 267 (75.4%) – – –
G 70 (17.6%) 87 (24.6%) G vs. T 1.527 (1.056–2.209) 0.024*
p – <0.001D* – – –
Controls (n = 199) HCV/HIV-1 patients (n = 53) Comparison OR (CI 95%) p
Genotype
TT 133 (66.8%) 33 (62.3%) – – –
TG 62 (31.2%) 19 (35.8%) GG+TG vs. TT 1.221 (0.621–2.395) 0.645
GG 4 (2.0%) 1 (1.9%) GG vs. TG+TT 0.938 (0.038–9.195) 1.000
p – 0.648E – – –
Allele
T 328 (82.4%) 85 (80.2%) – – –
G 70 (17.6%) 21 (19.8%) G vs. T 1.158 (0.648–2.055) 0.699
p – 0.676F – – –
HCV patients (n = 177) HCV/HIV-1 patients (n = 53) Comparison OR (CI 95%) p
Genotype
TT 96 (54.2%) 33 (62.3%) – – –
TG 75 (42.4%) 19 (35.8%) GG+TG vs. TT 0.718 (0.365–1.409) 0.382
GG 6 (3.4%) 1 (1.9%) GG vs. TG+TT 0.548 (0.024–4.762) 0.918
p – 0.327G – – –
Allele
T 267 (75.4%) 85 (80.2%) – – –
G 87 (24.6%) 21 (19.8%) G vs. T 0.758 (0.428–1.334) 0.377
p – 0.357H – – –
A,BControls vs. Patients (total); C,DControls vs. HCV Patients; E,FControls vs. HCV/HIV-1 Patients; G,HHCV Patients vs. HCV/HIV-1 Patients; OR, Odds ratio; CI,
Conﬁdence intervals. *Statistical signiﬁcance.
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genotypes (GG vs. TG+TT, OR = 0.548, p = 0.918; GG+TG vs.
TT, OR = 0.718, p = 0.382) or alleles (OR = 0.758, p = 0.377).
DISCUSSION
According to the World Health Organization [WHO] (2014),
350.000–500.000 people die every year from hepatitis C-related
illnesses. The mechanisms underlying the high HCV infection
persistence rate have not yet been fully elucidated. The exis-
tence of quasispecies and the wide mutation capability favor the
constant escape of the virus from the host immune response
(Strauss, 2001). Some virus- and host-related factors have been
associated with the persistence of HCV infection in affected
individuals, including the serum levels of HCV RNA, ethnicity,
coinfection with HIV, human leukocyte antigens (HLA) alle-
les, alcohol consumption, age at infection, and gender (Hofer
et al., 2003; Seeff and Hoofnagle, 2003; Yee, 2004; Hong et al.,
2005; Thomas et al., 2009; Rao et al., 2011). However, data
on the genetic host factors involved in the spontaneous clear-
ance of infection have been scarce until recently (García et al.,
2001).
IL28B gene encodes interferon-λ3, which belongs to an inter-
feron family characterized by powerful antiviral activity. This
cytokine is able to activate the cell signaling pathways that control
viral replication, e.g., the interferon-stimulated genes (ISG; Bal-
agopal et al., 2010). Recent studies have demonstrated the impact
of so-called favorable genotypes and alleles (CC andTT genotypes,
C and T alleles of polymorphisms rs8099917 and rs12979860,
respectively) on the response to the standard treatment for chronic
hepatitis C, as well as their relationship with spontaneous HCV
clearance in mono- and HIV coinfected individuals (Ge et al.,
2009; Suppiah et al., 2009; Tanaka et al., 2009; Thomas et al., 2009;
Aparicio et al., 2010; Rállon et al., 2010; Rauch et al., 2010).
One of the questions addressed by the present study concerns
the effect of the SNPs rs12979860 and rs8099917 on the host
resistance/susceptibility to HCV infection, which remains poorly
understood. García et al. (2001) raised the hypothesis that IL28B-
related polymorphisms might modulate, at least partially, the ISGs
and thus alter the natural history of HCV infection.
The study of Sarrazin et al. (2011), conducted in Germany,
identiﬁed signiﬁcant differences in the distribution of SNP
rs12979860 genotypes among the patients infected by HCV geno-
type 1 compared with non-infected individuals. The frequency
of the CC genotype was 49% in the group of non-infected indi-
viduals (n = 200) vs. 33.9% in the group of patients (n = 378,
p< 0.001). The authors suggested that the unfavorable rs12979860
genotype (TT) acts by predisposing the individuals to chronic
infection.
The study by Shi et al. (2012) in a Chinese population demon-
strated that the expression of the IL28B gene was signiﬁcantly
reduced in a group of patients with chronic hepatitis C (n = 529),
compared with individuals who exhibited spontaneous viral clear-
ance (n = 196, p = 0.003) and with non-infected individuals
(n = 171, p = 0.04). The authors suggested that the SNP
rs12979860 variants might exert a direct inﬂuence on the expres-
sion of IL28B and thus on the production of interferon-λ3. Similar
results were observed in theGerman study conducted by Langhans
et al. (2011), who noted that the levels of the IL28A/B genes were
signiﬁcantly higher among the carriers of the C allele compared
with the homozygous TT individuals (IL28A/B, p = 0.009).
In the study by Beinhardt et al. (2012), conducted in Austria,
the rs12979860CC genotypewas observedmore frequently among
patients with acute hepatitis C (n = 120) compared to the controls
(n = 96; 62.5% vs. 39.6%, p < 0.001) and was also observed more
frequently among patients who exhibited spontaneous viral clear-
ance compared to those with viral persistence (74.6% vs. 51.7%,
p = 0.021).
In the meta-analysis by Aalaei-Andabili et al. (2014), it was
found that rs12979860 CC genotype and C allele prevalences
among healthy subjects were similar to their distributions in geno-
types 2 and 3 HCV infected patients (favorable HCV genotypes)
in caucasian ethnicity, but they signiﬁcantly differed from the dis-
tributions in genotypes 1 and 4 HCV infected patients. It seems
that genotypes 1 and 4 HCV infected patients with a higher rate
of rs12979860 CC genotype and C allele could better eradicate
HCV RNA in the acute phase of HCV infection, versus genotypes
2 and 3. This ability leads to a lower rate of rs12979860 CC preva-
lence in the chronic phase of HCV infected patients, compared to
genotypes 2 and 3.
The study by Lunge et al. (2012) sought to assess the correla-
tion between the SNP rs12979860 and the spontaneous clearance
of HCV in a population of Brazilian HIV coinfected patients.
The genotype distribution differed signiﬁcantly in the group with
spontaneous viral clearance (CC: 52.9, CT : 32.4, and TT : 14.7%)
compared to the patients with chronic infection (CC: 28.8, CT :
60.6, and TT : 10.6%) (p < 0.05). The CT and TT genotypes
correlated with an almost threefold increase of the odds of devel-
oping chronic infection compared to theCC genotype (OR= 2.78,
p = 0.011).
In the present study, the results of the relative risk analysis
of the rs12979860 genotypes and alleles relative to the suscep-
tibility to HCV infection indicate that the TT+CT genotypes
and T allele exhibit a signiﬁcant association with the suggested
hypothesis. Curiously, the subgroup of coinfected patients exhib-
ited greater risk (OR = 3.000) when heterozygotes were included
in the analysis compared with the individuals with the TT geno-
type alone (OR = 1.583), which was further supported by the lack
of statistical signiﬁcance of the TT homozygotes.
Some authors have discussed the distribution and impact of the
rs8099917 variants in patients and controls. The Brazilian study
conducted by Ramos et al. (2012) with patients mono-infected
by HCV genotype 1 reported 48% patients with the TT genotype,
19% with theTG genotype, and 33% with the GG genotype, which
differs from the genotypic frequencies observed in the present
study – 54.2, 42.4 and 3.4%, respectively. Tanaka et al. (2009) con-
ducted a genome-wide association study (GWAS) in 154 Japanese
patients infected by HCV genotype 1 and observed a correlation
between the G allele and the low expression of the IL28B gene.
The study by Aparicio et al. (2010) with 160 HCV/HIV coinfected
patients in Spain observed a high frequency of the G allele in
patients infected by HCV genotypes 1 (40%) and 4 (42%).
The study by Vassilev et al. (2012) in Bulgaria sought to
assess the allelic frequency of rs8099917 in the overall population
(n = 79) and in a group of patients with chronic liver diseases
(n = 176). The authors observed that the favorable allele (T)
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occurred more frequently in the overall population (p = 0.0071).
Beinhardt et al. (2012) observed the rs8099917 TT genotype more
frequently in patients with acute hepatitis C compared with the
controls (83.3% vs. 69.8%, p = 0.018); the TT genotype was also
observed more frequently among the individuals who exhibited
spontaneous HCV clearance compared with those in whom the
virus persisted (91.5% vs. 75.0%, p = 0.025).
In the present study, an analysis of the relative risk of the
rs8099917 genotypes demonstrated that the GG+TG genotypes
and the G allele exhibited a positive correlation with chronic
infectionbyHCV in thepatient population, however, noneof these
correlations were observed in the group of coinfected patients
alone.
In both evaluated polymorphisms, the absence of an observed
effect in the group of HIV-coinfected patients does not imply nec-
essarily an absence of association. The small number of patients
sampled in this groupmight be a contributing factor for this result.
The absence of a signiﬁcant difference in the polymorphic distri-
bution of both genotypes and alleles between the mono- and the
coinfected patients, in addition to the lack of signiﬁcance in the
relative risk analysis, suggests that the results of the present study
apply to chronic HCV carriers and HIV coinfected patients. A
possible association of IL28B polymorphisms with the patient’s
condition on recruitment or clinical outcome was not investigated
since it did not belong to the study objectives.
Martin et al. (2010) and Nattermann et al. (2011) did not
observe any correlation between the SNP rs12979860 and HIV
mono-infected patients. There was no signiﬁcant difference in the
susceptibility to HIV infection, progression of infection, or the
clinical and laboratory parameters, such as serum viral RNA levels
and CD4+ cell count. Therefore, HIV appears to be associated
with SNPs near the IL28B gene only when there is coinfection by
HCV. The present study was not able to elucidate whether HIV
plays any role in the establishment of HCV infection.
Linkage disequilibrium between both SNPs revealed they were
highly associated in all groups of the study, suggesting a non-
random association that comprise the two main polymorphisms
near the IL28B gene. Similar results were reported by Suppiah et al.
(2009), Tanaka et al. (2009), Rauch et al. (2010), and Cavalcante
et al. (2012).
IL28B gene polymorphisms are known to be the most impor-
tant predictors for SVR to Peg-IFN/ribavirin therapy in genotype
1/4 and, on a smaller scale, in genotype 2/3 infected patients for
triple-therapies based on BOC/TVR in treatment-naïve patients
(Ge et al., 2009; Rauch et al., 2010; Jacobson et al., 2011; Poor-
dad et al., 2011; Fischer et al., 2012; Jiménez-Sousa et al., 2013;
Pol et al., 2013). The knowledge about variants of IL28B gene
polymorphisms is useful for decision-making therapy, provid-
ing individualized treatment options (Matsuura et al., 2014). For
example, patients who harbor the favorable genotype may receive
the usual treatment, while patients who have an unfavorable
genotype and/or are at higher risk of disease evolution shall be
treated with triple-therapy (Imazeki et al., 2010; Petta and Craxí,
2013). Moreover, patients with favorable genotype are more likely
to achieve SVR, possibly shortening the treatment time. Shorter
treatment schemes result in lower costs and also encouragepatients
to ﬁnish the treatment (Georgel et al., 2010).
In conclusion, the frequencies of the rs12979860 C allele and
CC genotype and the rs8099917 T allele and TT genotype were
signiﬁcantly higher in the group of non-infected individuals com-
pared with mono- and HIV-1 coinfected patients with chronic
HCV infection. The rs12979860TT genotype andT allele behaved
as signiﬁcant risk factors forHCV infection in themono- and coin-
fected patients, whereas the rs8099917 GG genotype and G allele
represented risk factors for the mono-infected patients in partic-
ular. The present study was unable to clarify whether rs12979860
and rs8099917 variants exert a signiﬁcant inﬂuence on the estab-
lishment of HCV infection in individuals also infected with HIV.
Based on our results, we suggest that SNPs near the IL28B gene
exert a signiﬁcant inﬂuence on the establishment of HCV infec-
tion, contributing to a better understanding of the susceptibility
to and the natural history of hepatitis C.
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